Associations of cardiac stress biomarkers with incident type 2 diabetes and changes in glucose metabolism: KORA F4/FF4 study.
Adrenomedullin
/ blood
Adult
Aged
Aged, 80 and over
Biomarkers
/ blood
Blood Glucose
/ metabolism
Diabetes Mellitus, Type 2
/ blood
Female
Germany
/ epidemiology
Glycopeptides
/ blood
Heart Diseases
/ blood
Humans
Incidence
Insulin Resistance
Male
Middle Aged
Peptide Fragments
/ blood
Prediabetic State
/ blood
Prognosis
Prospective Studies
Protein Precursors
/ blood
Risk Assessment
Risk Factors
Time Factors
CT-proET-1
Cardiac stress biomarkers
Cohort study
Copeptin
Incidence
Insulin resistance
MR-proADM
MR-proANP
Prediabetes
Type 2 diabetes
Journal
Cardiovascular diabetology
ISSN: 1475-2840
Titre abrégé: Cardiovasc Diabetol
Pays: England
ID NLM: 101147637
Informations de publication
Date de publication:
16 10 2020
16 10 2020
Historique:
received:
23
06
2020
accepted:
12
09
2020
entrez:
17
10
2020
pubmed:
18
10
2020
medline:
8
6
2021
Statut:
epublish
Résumé
High N-terminal pro-brain-type natriuretic peptide levels have been associated with a lower risk of type 2 diabetes mellitus (T2D). However, less is known about other cardiac stress biomarkers in this context. Here we evaluated the association of mid-regional pro-atrial natriuretic peptide (MR-proANP), C-terminal pro-arginine vasopressin (copeptin), C-terminal pro-endothelin-1 (CT-proET-1) and mid-regional pro-adrenomedullin (MR-proADM) with incident T2D and changes in glucose metabolism. We performed a prospective cohort study using data from the population-based KORA F4/FF4 study. 1773 participants (52.3% women) with MR-proANP measurements and 960 (52.7% women) with copeptin, CT-proET-1 and MR-proADM measurements were included. We examined associations of circulating plasma levels of MR-proANP, copeptin, CT-proET-1 and MR-proADM with incident T2D, the combined endpoint of incident prediabetes/T2D and with fasting and 2 h-glucose, fasting insulin, HOMA-IR, HOMA-B and HbA1c at follow-up. Logistic and linear regression models adjusted for age, sex, waist circumference, height, hypertension, total/HDL cholesterol ratio, triglycerides, smoking, physical activity and parental history of diabetes were used to compute effect estimates. During a median follow-up time of 6.4 years (25th and 75th percentiles: 6.0 and 6.6, respectively), 119 out of the 1773 participants and 72 out of the 960 participants developed T2D. MR-proANP was inversely associated with incident T2D (odds ratio [95% confidence interval]: 0.75 [0.58; 0.96] per 1-SD increase of log MR-proANP). Copeptin was positively associated with incident prediabetes/T2D (1.29 [1.02; 1.63] per 1-SD increase of log copeptin). Elevated levels of CT-proET-1 were associated with increased HOMA-B at follow-up, while elevated MR-proADM levels were associated with increased fasting insulin, HOMA-IR and HOMA-B at follow-up. These associations were independent of previously described diabetes risk factors. High plasma concentrations of MR-proANP contributed to a lower risk of incident T2D, whereas high plasma concentrations of copeptin were associated with an increased risk of incident prediabetes/T2D. Furthermore, high plasma concentrations of CT-proET-1 and MR-proADM were associated with increased insulin resistance. Our study provides evidence that biomarkers implicated in cardiac stress are associated with incident T2D and changes in glucose metabolism.
Sections du résumé
BACKGROUND
High N-terminal pro-brain-type natriuretic peptide levels have been associated with a lower risk of type 2 diabetes mellitus (T2D). However, less is known about other cardiac stress biomarkers in this context. Here we evaluated the association of mid-regional pro-atrial natriuretic peptide (MR-proANP), C-terminal pro-arginine vasopressin (copeptin), C-terminal pro-endothelin-1 (CT-proET-1) and mid-regional pro-adrenomedullin (MR-proADM) with incident T2D and changes in glucose metabolism.
METHODS
We performed a prospective cohort study using data from the population-based KORA F4/FF4 study. 1773 participants (52.3% women) with MR-proANP measurements and 960 (52.7% women) with copeptin, CT-proET-1 and MR-proADM measurements were included. We examined associations of circulating plasma levels of MR-proANP, copeptin, CT-proET-1 and MR-proADM with incident T2D, the combined endpoint of incident prediabetes/T2D and with fasting and 2 h-glucose, fasting insulin, HOMA-IR, HOMA-B and HbA1c at follow-up. Logistic and linear regression models adjusted for age, sex, waist circumference, height, hypertension, total/HDL cholesterol ratio, triglycerides, smoking, physical activity and parental history of diabetes were used to compute effect estimates.
RESULTS
During a median follow-up time of 6.4 years (25th and 75th percentiles: 6.0 and 6.6, respectively), 119 out of the 1773 participants and 72 out of the 960 participants developed T2D. MR-proANP was inversely associated with incident T2D (odds ratio [95% confidence interval]: 0.75 [0.58; 0.96] per 1-SD increase of log MR-proANP). Copeptin was positively associated with incident prediabetes/T2D (1.29 [1.02; 1.63] per 1-SD increase of log copeptin). Elevated levels of CT-proET-1 were associated with increased HOMA-B at follow-up, while elevated MR-proADM levels were associated with increased fasting insulin, HOMA-IR and HOMA-B at follow-up. These associations were independent of previously described diabetes risk factors.
CONCLUSIONS
High plasma concentrations of MR-proANP contributed to a lower risk of incident T2D, whereas high plasma concentrations of copeptin were associated with an increased risk of incident prediabetes/T2D. Furthermore, high plasma concentrations of CT-proET-1 and MR-proADM were associated with increased insulin resistance. Our study provides evidence that biomarkers implicated in cardiac stress are associated with incident T2D and changes in glucose metabolism.
Identifiants
pubmed: 33066780
doi: 10.1186/s12933-020-01117-1
pii: 10.1186/s12933-020-01117-1
pmc: PMC7566143
doi:
Substances chimiques
Biomarkers
0
Blood Glucose
0
Glycopeptides
0
Peptide Fragments
0
Protein Precursors
0
copeptins
0
mid-regional pro-adrenomedullin, human
0
Adrenomedullin
148498-78-6
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
178Références
Arch Med Res. 2020 Aug;51(6):548-555
pubmed: 32505416
J Clin Endocrinol Metab. 2009 Jul;94(7):2558-64
pubmed: 19366852
Endocrinology. 1996 Jun;137(6):2626-32
pubmed: 8641217
Biochem Biophys Res Commun. 1998 Mar 17;244(2):325-31
pubmed: 9514921
Diabetes. 2007 Mar;56(3):728-34
pubmed: 17327443
PLoS Med. 2011 Oct;8(10):e1001112
pubmed: 22039354
J Cardiol. 2019 May;73(5):379-385
pubmed: 30591319
Atherosclerosis. 2013 Oct;230(2):235-41
pubmed: 24075750
J Clin Endocrinol Metab. 2016 Jun;101(6):2432-9
pubmed: 27049477
J Clin Endocrinol Metab. 2012 Feb;97(2):638-45
pubmed: 22112816
Eur J Endocrinol. 2012 Dec;167(6):847-53
pubmed: 23002189
Circulation. 2004 Sep 14;110(11):1507-12
pubmed: 15364819
Diabetologia. 2014 Jan;57(1):16-29
pubmed: 24078135
J Clin Endocrinol Metab. 2015 Sep;100(9):3332-9
pubmed: 26158609
Crit Care. 2018 Feb 9;22(1):33
pubmed: 29422070
Diabetologia. 2012 Jul;55(7):1963-70
pubmed: 22526609
Diabetes Care. 2006 May;29(5):1130-9
pubmed: 16644654
Hypertension. 2018 Aug;72(2):270-276
pubmed: 29941512
Physiol Rev. 2012 Oct;92(4):1813-64
pubmed: 23073632
Diabetologia. 1996 Sep;39(9):1030-5
pubmed: 8877285
J Hypertens. 2019 Mar;37(3):590-595
pubmed: 30540625
Metabolism. 2000 Feb;49(2):264-9
pubmed: 10690956
Cardiovasc Diabetol. 2019 Mar 29;18(1):44
pubmed: 30922297
Clin Endocrinol (Oxf). 2019 Jul;91(1):22-32
pubmed: 31004513
Diabetes Care. 2007 Jun;30(6):1513-9
pubmed: 17384335
Metabolism. 2016 Oct;65(10):1489-97
pubmed: 27621184
Diabetologia. 2003 Feb;46(2):182-9
pubmed: 12627316
Eur J Epidemiol. 2019 Apr;34(4):409-422
pubmed: 30599058
PLoS One. 2011;6(8):e22932
pubmed: 21850244
Ann Intern Med. 2014 Jan 21;160(2):122-31
pubmed: 24592497
J Endocrinol Invest. 2012 Jun;35(6):553-6
pubmed: 21791966
Am J Hypertens. 2002 Nov;15(11):967-72
pubmed: 12441216
Endocrinology. 2007 Apr;148(4):1835-42
pubmed: 17194742
Diabetes. 2011 Aug;60(8):2061-7
pubmed: 21677282
Diabetologia. 2007 May;50(5):1038-47
pubmed: 17318625
Hypertension. 2003 May;41(5):1080-5
pubmed: 12668590
Atherosclerosis. 2016 Sep;252:88-96
pubmed: 27508320
Stat Med. 2011 Jan 15;30(1):11-21
pubmed: 21204120
Circulation. 2004 Feb 10;109(5):594-600
pubmed: 14769680
Biometrics. 1988 Sep;44(3):837-45
pubmed: 3203132
Circulation. 2010 May 18;121(19):2102-8
pubmed: 20439785
Cardiovasc Diabetol. 2018 Aug 2;17(1):110
pubmed: 30071874
J Clin Endocrinol Metab. 2016 Apr;101(4):1372-80
pubmed: 26815880
Diabetes Care. 2003 Aug;26(8):2433-41
pubmed: 12882875
Circulation. 2007 Mar 20;115(11):1345-53
pubmed: 17339551
Int J Cardiol. 2018 Jan 1;250:188-194
pubmed: 29074040
PLoS One. 2010 Apr 09;5(4):e10100
pubmed: 20396381